Publicaciones en colaboración con investigadores/as de University of Münster (26)

2024

  1. A robust clustering strategy for stratification unveils unique patient subgroups in acutely decompensated cirrhosis

    Journal of Translational Medicine, Vol. 22, Núm. 1

  2. Gliomatosis cerebri in children: A poor prognostic phenotype of diffuse gliomas with a distinct molecular profile

    Neuro-oncology, Vol. 26, Núm. 9, pp. 1723-1737

2020

  1. Correction to: A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer’s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity (Acta Neuropathologica, (2019), 138, 2, (237-250), 10.1007/s00401-019-02026-8)

    Acta Neuropathologica

  2. Wnt signaling and Loxl2 promote aggressive osteosarcoma

    Cell Research, Vol. 30, Núm. 10, pp. 885-901

2019

  1. Dendritic cells and T cells interact within murine afferent lymphatic capillaries

    Frontiers in Immunology, Vol. 10, Núm. MAR

  2. Tolerogenic dendritic cell-based treatment for multiple sclerosis (MS): A harmonised study protocol for two phase i clinical trials comparing intradermal and intranodal cell administration

    BMJ Open, Vol. 9, Núm. 9

2017

  1. Long-term survival of patients with CLL after allogeneic transplantation: A report from the European Society for Blood and Marrow Transplantation

    Bone Marrow Transplantation, Vol. 52, Núm. 3, pp. 372-380

2016

  1. Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies

    Cancer, Vol. 122, Núm. 14, pp. 2178-2185

2011

  1. Bone Sarcomas

    INTRAOPERATIVE IRRADIATION: TECHNIQUES AND RESULTS, SECOND EDITION (HUMANA PRESS INC), pp. 407-429

  2. Central Nervous System Tumors

    INTRAOPERATIVE IRRADIATION: TECHNIQUES AND RESULTS, SECOND EDITION (HUMANA PRESS INC), pp. 141-161

  3. Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: Analysis of the VISTA trial

    British Journal of Haematology, Vol. 153, Núm. 2, pp. 212-221

  4. Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. Melphalan-prednisone in the phase III VISTA trial in multiple myeloma

    European Journal of Haematology, Vol. 86, Núm. 5, pp. 372-384

  5. Multiple myeloma treatment strategies with novel agents in 2011: A European perspective

    Oncologist, Vol. 16, Núm. 4, pp. 388-403

  6. Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: Subanalysis of the phase 3 VISTA study

    European Journal of Haematology, Vol. 86, Núm. 1, pp. 23-31

  7. Treatment of relapsed and refractory multiple myeloma in the era of novel agents

    Cancer Treatment Reviews, Vol. 37, Núm. 4, pp. 266-283

2010

  1. Current multiple myeloma treatment strategies with novel agents: A European perspective

    Oncologist, Vol. 15, Núm. 1, pp. 6-25

  2. Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: Analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone

    Blood, Vol. 116, Núm. 19, pp. 3743-3750

  3. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues

    The Lancet Oncology, Vol. 11, Núm. 11, pp. 1086-1095

2009

  1. A Prolonged Therapy Improves Quality of Response, and CR Associated with Superior Outcomes, with VMP

    CLINICAL LYMPHOMA & MYELOMA

  2. Bortezomib and Melphalan as Part of VMP Are Associated with Similar Hematologic Toxicity to MP Alone

    CLINICAL LYMPHOMA & MYELOMA